China’s Regulator Has New Head But Will He Advance Further Reforms?
IP Protection On Agenda?
A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.
You may also be interested in...
The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for the Chinese biopharma sector.
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.
Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.